Cancer Treatment in Australia: Health Economics Analysis and Report

This report examines the health economics of cancer treatment in Australia, focusing on lymphoma and its subtypes, including Hodgkin's and non-Hodgkin's lymphoma. It analyzes the incidence of these cancers, their impact on different age groups and genders, and mortality rates. The report also compares the costs and projected revenue of two treatment methods, Nano Surgery and Phage therapy, from 2018-19 to 2022-23, highlighting differences in employment costs, goods and services costs, and potential returns. The analysis aims to inform resource allocation decisions within the Australian healthcare system, considering the increasing burden of cancer and the need for effective, cost-efficient treatments.

Health Economics
The number of cancer patients, both male and female, will be increased and will be
increased in upcoming years. For the government of Australia, cancer treatment becomes a
burden. Therefore, proper allocation of resources and planning are needed to control this disease.
Lymphoma has ICD-10 cancer codes. C81 for Hodgkin’s disease, C82 for follicular non-
Hodgkin’s lymphoma, C83 for diffuse non-Hodgkin’s lymphoma, C84 for peripheral and
cutaneous T-cell lymphomas and C85-C86 for the types of non-Hodgkin’s lymphoma.
Hodgkin cancer is a very rare type of cancer. This type of cancer especially effects people
with young age of an average of 40 years. Males can survive more in this diseases, compare to
female persons.
Non-Hodgkin disease is common among males in Australia. This disease can be found
among people of an average age of 65 years.
People, aged 50-54 and above, have the highest tendency to die from Leukemia.
Mortality rate among makes are higher compare to females. However, children, aged between 0-
4 also suffer from this disease.
Total project cost for Nano Surgery is $250,000 and for Phage therapy $200,000.
Comparing total employment cost of these two investments from the year 2018-19 to 2022-23, it
can be said that this cost structure is high for Nano Surgery compare to Phage therapy. Total
goods and serivces costs are also higher for Nano surgery, compare to Phage therapy during
1918-19 and 2022-23. However, the projected return from revenue is higher in Nano surgery
compare to Phage therapy during this time period.